Prevention of transfusion-transmitted infections

Blood

Volumn 133, Issue 17, 2019, Pages 1854-1864

  Busch, Michael P ^a,b   Bloch, Evan M ^c   Kleinman, Steven ^d  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BABESIA MICROTI; BLOOD DONOR; BLOOD SAFETY; BLOOD TRANSFUSION; COST EFFECTIVENESS ANALYSIS; DISEASE BURDEN; DISEASE TRANSMISSION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HIGH INCOME COUNTRY; HUMAN; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2; INCIDENCE; INFECTION; INFECTION PREVENTION; INFECTIOUS AGENT; NONHUMAN; NUCLEIC ACID AMPLIFICATION; PRIORITY JOURNAL; RECIPIENT; REVIEW; RISK REDUCTION; UNITED STATES; VIRUS TYPING; WEST NILE VIRUS; ZIKA VIRUS; ADVERSE EVENT; BLOOD COMPONENT THERAPY; BLOOD TRANSFUSION REACTION; PROGNOSIS;

BLOOD COMPONENT TRANSFUSION; HUMANS; PROGNOSIS; TRANSFUSION REACTION;

EID: 85065299876     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2018-11-833996     Document Type: Review

References (130)

1. Stramer SL, Hollinger FB, Katz LM, et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion. 2009;49(suppl 2):1S-29S.
2. Glynn SA, Busch MP, Dodd RY, et al; NHLBI Emerging Infectious Disease Task Force convened November 7, 2011. Emerging infectious agents and the nation’s blood supply: responding to potential threats in the 21st century. Transfusion. 2013;53(2): 438-454.
3. Atreya C, Nakhasi H, Mied P, et al. FDA workshop on emerging infectious diseases: evaluating emerging infectious diseases (EIDs) for transfusion safety. Transfusion. 2011;51(8):1855-1871.
4. Perkins HA, Busch MP. Transfusion-associated infections: 50 years of relentless challenges and remarkable progress. Transfusion. 2010;50(10):2080-2099.
5. Alter HJ, Klein HG. The hazards of blood transfusion in historical perspective. Blood. 2008;112(7):2617-2626.
6. Busch M. Infectious risks of blood transfusions: recent advances in testing technologies and new approaches to surveillance and decision-making. ISBT Sci Ser. 2014;9(1): 276-280.
7. Stramer SL, Dodd RY; AABB Transfusion-Transmitted Diseases Emerging Infectious Diseases Subgroup. Transfusion-transmitted emerging infectious diseases: 30 years of challenges and progress. Transfusion. 2013; 53(10 Pt 2):2375-2383.
8. Busch MP, Caglioti S, Robertson EF, et al. Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing. N Engl J Med. 2005;353(5):460-467.
9. Stramer SL, Fang CT, Foster GA, Wagner AG, Brodsky JP, Dodd RY. West Nile virus among blood donors in the United States, 2003 and 2004. N Engl J Med. 2005;353(5):451-459.
10. Galel SA, Williamson PC, Busch MP, et al; cobas Zika IND Study Group. First Zika-positive donations in the continental United States. Transfusion. 2017;57(3 Pt 2):762-769.
11. Williamson PC, Linnen JM, Kessler DA, et al. First cases of Zika virus-infected US blood donors outside states with areas of active transmission. Transfusion. 2017;57(3 Pt 2): 770-778.
12. Petrik J, Lozano M, Seed CR, et al. Hepatitis E. Vox Sang. 2016;110(1):93-130.
13. Hewitt PE, Ijaz S, Brailsford SR, et al. Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet. 2014;384(9956):1766-1773.
14. Kleinman S, Stassinopoulos A. Risks associated with red blood cell transfusions: potential benefits from application of pathogen inactivation. Transfusion. 2015;55(12): 2983-3000.
15. Kleinman S, Reed W, Stassinopoulos A. A patient-oriented risk-benefit analysis of pathogen-inactivated blood components: application to apheresis platelets in the United States. Transfusion. 2013;53(7): 1603-1618.
16. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med. 1996;334(26):1685-1690.
17. Glynn SA, Kleinman SH, Wright DJ, Busch MP; NHLBI Retrovirus Epidemiology Donor Study. International application of the incidence rate/window period model. Transfusion. 2002;42(8):966-972.
18. Kleinman SH, Lelie N, Busch MP. Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion. 2009;49(11):2454-2489.
19. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003;17(13):1871-1879.
20. Biswas R, Tabor E, Hsia CC, et al. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion. 2003;43(6):788-798.
21. Glynn SA, Wright DJ, Kleinman SH, et al. Dynamics of viremia in early hepatitis C virus infection. Transfusion. 2005;45(6):994-1002.
22. Busch MP, Murthy KK, Kleinman SH, et al. Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA-licensed assays: implications for transfusion safety and HCV infection outcomes. Blood. 2012;119(26):6326-6334.
23. Stramer SL, Glynn SA, Kleinman SH, et al; National Heart, Lung, and Blood Institute Nucleic Acid Test Study Group. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med. 2004; 351(8):760-768.
24. Roth WK, Busch MP, Schuller A, et al. International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang. 2012; 102(1):82-90.
25. Bruhn R, Lelie N, Custer B, Busch M, Kleinman S; International NAT Study Group. Prevalence of human immunodeficiency virus RNA and antibody in first-time, lapsed, and repeat blood donations across five international regions and relative efficacy of alternative screening scenarios. Transfusion. 2013;53(10 Pt 2):2399-2412.
26. Bruhn R, Lelie N, Busch M, Kleinman S; International NAT Study Group. Relative efficacy of nucleic acid amplification testing and serologic screening in preventing hepatitis C virus transmission risk in seven international regions. Transfusion. 2015;55(6):1195-1205.
27. Custer B. Health economics in blood safety. In: Sha H, Dodd RY, eds. Blood Safety: A Guide to Monitoring and Responding to Potential New Threats. Cham, Switzerland: Springer International Publishing; 2019: 53-81.
28. Janssen MP, van Hulst M, Custer B, ABO RBDM Health Economics and Outcomes Working Group & Collaborators. An assessment of differences in costs and health benefits of serology and NAT screening of donations for blood transfusion in different western countries. [published correction appears in Vox Sang. 2018;113(1):88]. Vox Sang. 2017;112(6):518-525.
29. Sullivan MT, Williams AE, Fang CT, Grandinetti T, Poiesz BJ, Ehrlich GD; The American Red Cross HTLV-I/II Collaborative Study Group. Transmission of human T-lymphotropic virus types I and II by blood transfusion. A retrospective study of recipients of blood components (1983 through 1988). Arch Intern Med. 1991;151(10): 2043-2048.
30. Kleinman S, Swanson P, Allain JP, Lee H. Transfusion transmission of human T-lymphotropic virus types I and II: serologic and polymerase chain reaction results in recipients identified through look-back investigations. Transfusion. 1993;33(1): 14-18.
31. Fiebig E, Murphy EL, Busch MP. Human immunodeficiency virus, human T-cell lymphotropic viruses, and other retroviruses. In: Hillyer CD, Silberstein LE, Ness PM, Anderson KC, Roback JD, eds. Blood Banking and Transfusion Medicine: Basic Principles and Practice. Philadelphia, PA: Churchill Livingstone; 2009:447-464.
32. Drew WL, Tegtmeier G, Alter HJ, Laycock ME, Miner RC, Busch MP. Frequency and duration of plasma CMV viremia in sero-converting blood donors and recipients. Transfusion. 2003;43(3):309-313.
33. Ziemann M, Juhl D, Görg S, Hennig H. The impact of donor cytomegalovirus DNA on transfusion strategies for at-risk patients. Transfusion. 2013;53(10):2183-2189.
34. Hudnall SD, Chen T, Allison P, Tyring SK, Heath A. Herpesvirus prevalence and viral load in healthy blood donors by quantitative real-time polymerase chain reaction. Transfusion. 2008;48(6):1180-1187.
35. Compston LI, Sarkobie F, Li C, Candotti D, Opare-Sem O, Allain JP. Multiplex real-time PCR for the detection and quantification of latent and persistent viral genomes in cellular or plasma blood fractions. J Virol Methods. 2008;151(1):47-54.
36. Juhl D, Mosel C, Nawroth F, et al. Detection of herpes simplex virus DNA in plasma of patients with primary but not with recurrent infection: implications for transfusion medicine? Transfus Med. 2010;20(1):38-47.
37. Hudnall SD, Chen T, Rady P, Tyring S, Allison P. Human herpesvirus 8 seroprevalence and viral load in healthy adult blood donors. Transfusion. 2003;43(1):85-90.
38. Vamvakas EC. Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Transfus Med Rev. 2005;19(3): 181-199.
39. Smith D, Lu Q, Yuan S, Goldfinger D, Fernando LP, Ziman A. Survey of current practice for prevention of transfusion-transmitted cytomegalovirus in the United States: leucoreduction vs. cytomegalovirus-seronegative. Vox Sang. 2010;98(1):29-36.
40. Petersen LR, Busch MP. Transfusion-transmitted arboviruses. Vox Sang. 2010; 98(4):495-503.
41. Pealer LN, Marfin AA, Petersen LR, et al; West Nile Virus Transmission Investigation Team. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med. 2003;349(13): 1236-1245.
42. Dodd RY, Foster GA, Stramer SL. Keeping blood transfusion safe from West Nile virus: American Red Cross experience, 2003 to 2012. Transfus Med Rev. 2015;29(3): 153-161.
43. Betsem E, Kaidarova Z, Stramer SL, et al. Correlation of West Nile virus incidence in donated blood with West Nile neuroinvasive disease rates, United States, 2010-2012. Emerg Infect Dis. 2017;23(2):212-219.
44. Lanteri MC, Busch MP. Dengue in the context of “safe blood” and global epidemiology: to screen or not to screen? Transfusion. 2012;52(8):1634-1639.
45. Sabino EC, Loureiro P, Lopes ME, et al; International Component of the NHLBI Recipient Epidemiology and Donor Evaluation Study-III. Transfusion-transmitted dengue and associated clinical symptoms during the 2012 epidemic in Brazil. J Infect Dis. 2016; 213(5):694-702.
46. Busch MP, Sabino EC, Brambilla D, et al; International Component of the NHLBI Recipient Epidemiology and Donor Evaluation Study-III (REDS-III). Duration of dengue viremia in blood donors and relationships between donor viremia, infection incidence and clinical case reports during a large epidemic. J Infect Dis. 2016;214(1):49-54.
47. Simmons G, Brès V, Lu K, et al. High incidence of Chikungunya virus and frequency of viremic blood donations during epidemic, Puerto Rico, USA, 2014. Emerg Infect Dis. 2016;22(7):1221-1228.
48. Petersen LR, Jamieson DJ, Powers AM, Honein MA. Zika virus. N Engl J Med. 2016; 374(16):1552-1563.
49. Food and Drug Administration. Recommendations for Donor Screening. Deferral, and Product Management to Reduce the Risk of Transfusion-Transmission of Zika Virus. Silver Spring, MD: US Department of Health and Human Services; 2016.
50. Chevalier MS, Biggerstaff BJ, Basavaraju SV, et al. Use of blood donor screening data to estimate Zika virus incidence, Puerto Rico, April-August 2016. Emerg Infect Dis. 2017; 23(5):790-795.
51. Food and Drug Administration. Revised Recommendations for Reducing the Risk of Zika Virus Transmission by Blood and Blood Components: Guidance for Industry. Silver Spring, MD: US Department of Health and Human Services; 2018.
52. Saá P, Proctor M, Foster G, et al. Investigational testing for Zika virus among U.S. blood donors. N Engl J Med. 2018; 378(19):1778-1788.
53. Ellingson KD, Sapiano MRP, Haass KA, et al. Cost projections for implementation of safety interventions to prevent transfusion-transmitted Zika virus infection in the United States. Transfusion. 2017;57(suppl 2): 1625-1633.
54. Bloch EM, Ness PM, Tobian AAR, Sugarman J. Revisiting blood safety practices given emerging data about zika Virus. N Engl J Med. 2018;378(19):1837-1841.
55. Russel WA, Stramer SL, Busch MP, Custer B. Screening the blood supply for Zika virus in the 50 U.S. states and Puerto Rico: a cost-effectiveness analysis. Ann Intern Med. 2019; 170(3):164-174.
56. Jimenez A, Shaz BH, Bloch EM. Zika virus and the blood supply: what do we know? Transfus Med Rev. 2017;31(1):1-10.
57. Leiby D, O’Brien SF, Wendel S, et al; WPTTID Subgroup on Parasites. International survey on the impact of parasitic infections: frequency of transmission and current mitigation strategies. Vox Sang. 2019;114(1):17-27.
58. Siegel SE, Lunde MN, Gelderman AH, et al. Transmission of toxoplasmosis by leukocyte transfusion. Blood. 1971;37(4):388-394.
59. Jimenez-Marco T, Fisa R, Girona-Llobera E, et al. Transfusion-transmitted leishmaniasis: a practical review. Transfusion. 2016; 56(suppl 1):S45-S51.
60. Food and Drug Administration. Topic I: Issue Summary: Strategies for Implementation of Antibody and Nucleic Acid-based Testing for Babesia microti in Blood Donors. Silver Spring, MD: US Department of Health and Human Services; 2015.
61. Krause PJ, Spielman A, Telford SR III, et al. Persistent parasitemia after acute babesiosis. N Engl J Med. 1998;339(3):160-165.
62. Herwaldt BL, Linden JV, Bosserman E, Young C, Olkowska D, Wilson M. Transfusion-associated babesiosis in the United States: a description of cases. Ann Intern Med. 2011; 155(8):509-519.
63. Vannier E, Krause PJ. Human babesiosis. N Engl J Med. 2012;366(25):2397-2407.
64. Bloch EM, Herwaldt BL, Leiby DA, et al. The third described case of transfusion-transmitted Babesia duncani. Transfusion. 2012;52(7):1517-1522.
65. Levin AE, Williamson PC, Bloch EM, et al. Serologic screening of United States blood donors for Babesia microti using an investigational enzyme immunoassay. Transfusion. 2016;56(7):1866-1874.
66. Moritz ED, Winton CS, Johnson ST, et al. Investigational screening for Babesia microti in a large repository of blood donor samples from nonendemic and endemic areas of the United States. Transfusion. 2014;54(9): 2226-2236.
67. Brès V, Self D, Ocampo D, et al. Performance characteristics of a transcription-mediated amplification assay on a fully automated system to detect Babesia in blood donations. In: Proceedings of the AABB Annual Meeting; 22-25 October 2016; Orlando, FL.
68. Moritz ED, Winton CS, Tonnetti L, et al. Screening for Babesia microti in the U.S. blood supply. N Engl J Med. 2016;375(23): 2236-2245.
69. Bakkour S, Chafets DM, Wen L, et al. Minimal infectious dose and dynamics of Babesia microti parasitemia in a murine model. Transfusion. 2018;58(12):2903-2910.
70. Ward SJ, Stramer SL, Szczepiorkowski ZM. Assessing the risk of Babesia to the United States blood supply using a risk-based decision-making approach: Report of AABB’s Ad Hoc Babesia Policy Working Group (original report). Transfusion. 2018; 58(8):1916-1923.
71. Custer B, Agapova M, Bruhn R, et al. Epidemiologic and laboratory findings from 3 years of testing United States blood donors for Trypanosoma cruzi. Transfusion. 2012; 52(9):1901-1911.
72. Centers for Disease Control and Prevention (CDC). Blood donor screening for chagas disease-United States, 2006-2007. MMWR Morb Mortal Wkly Rep. 2007;56(7):141-143.
73. Dodd R, Groves JA, Townsend RL, et al. Impact of one-time testing for Trypanosoma cruzi antibodies among blood donors in the United States. Transfusion. 2019;59(3): 1016-1023.
74. Food and Drug Administration. Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Blood and Blood Components: Guidance for Industry. Silver Spring, MD: US Department of Health and Human Services; 2017.
75. Food and Drug Administration. Recommendations for Donor Questioning, Deferral, Reentry and Product Management to Reduce the Risk of Transfusion-Transmitted Malaria. Silver Spring, MD: US Department of Health and Human Services; 2013.
76. Mungai M, Tegtmeier G, Chamberland M, Parise M. Transfusion-transmitted malaria in the United States from 1963 through 1999. N Engl J Med. 2001;344(26):1973-1978.
77. Bloch EM. Residual risk of bacterial contamination: what are the options? Transfusion. 2017;57(10):2289-2292.
78. Erony SM, Marshall CE, Gehrie EA, et al. The epidemiology of bacterial culture-positive and septic transfusion reactions at a large tertiary academic center: 2009 to 2016. Transfusion. 2018;58(8):1933-1939.
79. Hong H, Xiao W, Lazarus HM, Good CE, Maitta RW, Jacobs MR. Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance. Blood. 2016;127(4):496-502.
80. Brecher ME, Hay SN. Bacterial contamination of blood components. Clin Microbiol Rev. 2005;18(1):195-204.
81. Fuller AK, Uglik KM, Savage WJ, Ness PM, King KE. Bacterial culture reduces but does not eliminate the risk of septic transfusion reactions to single-donor platelets. Transfusion. 2009;49(12):2588-2593.
82. Hong H, Xiao W, Lazarus HM, Good CE, Maitta RW, Jacobs MR. Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance. Blood. 2016;127(4):496-502.
83. Bloch EM, Marshall CE, Boyd JS, et al. Implementation of secondary bacterial culture testing of platelets to mitigate residual risk of septic transfusion reactions. Transfusion. 2018;58(7):1647-1653.
84. Li JW, Brecher ME, Jacobson JL, et al. Addressing the risk of bacterial contamination in platelets: a hospital economic perspective. Transfusion. 2017;57(10): 2321-2328.
85. Food and Drug Administration. Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion: Draft Guidance for Industry. Silver Spring, MD: US Department of Health and Human Services; 2018.
86. Urwin PJ, Mackenzie JM, Llewelyn CA, Will RG, Hewitt PE. Creutzfeldt-Jakob disease and blood transfusion: updated results of the UK Transfusion Medicine Epidemiology Review study. Vox Sang. 2016;110(4):310-316.
87. Crowder LA, Schonberger LB, Dodd RY, Steele WR. Creutzfeldt-Jakob disease look-back study: 21 years of surveillance for transfusion transmission risk. Transfusion. 2017;57(8):1875-1878.
88. Turner ML, Ludlam CA. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products. Br J Haematol. 2009;144(1):14-23.
89. Zou S, Fang CT, Schonberger LB. Transfusion transmission of human prion diseases. Transfus Med Rev. 2008;22(1):58-69.
90. Ponte ML. Insights into the management of emerging infections: regulating variant Creutzfeldt-Jakob disease transfusion risk in the UK and the US. PLoS Med. 2006;3(10): e342.
91. Hewitt PE, Llewelyn CA, Mackenzie J, Will RG. Three reported cases of variant Creutzfeldt-Jakob disease transmission following transfusion of labile blood components. Vox Sang. 2006;91(4):348.
92. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet. 2004;364(9433): 527-529.
93. Coste J, Prowse C, Grabmer C, et al. Prion reduction of red-blood-cells. Vox Sang. 2012;103(3):260-272.
94. Concha-Marambio L, Pritzkow S, Moda F, et al. Detection of prions in blood from patients with variant Creutzfeldt-Jakob disease. Sci Transl Med. 2016;8(370):370ra183.
95. Bougard D, Brandel JP, Bélondrade M, et al. Detection of prions in the plasma of presymptomatic and symptomatic patients with variant Creutzfeldt-Jakob disease. Sci Transl Med. 2016;8(370):370ra182.
96. Diack AB, Will RG, Manson JC. Public health risks from subclinical variant CJD. PLoS Pathog. 2017;13(11):e1006642.
97. Morales R, Duran-Aniotz C, Castilla J, Estrada LD, Soto C. De novo induction of amyloid-b deposition in vivo. Mol Psychiatry. 2012; 17(12):1347-1353.
98. Prusiner SB. Cell biology. A unifying role for prions in neurodegenerative diseases. Science. 2012;336(6088):1511-1513.
99. Edgren G, Hjalgrim H, Rostgaard K, et al. Transmission of neurodegenerative disorders through blood transfusion: a cohort study. Ann Intern Med. 2016;165(5):316-324.
100. Dodd RY. Emerging infections and transfusion safety. In: Murphy MF, Pamphilon DH, Heddle NM, eds. Practical Transfusion Medicine. 4th ed. West Sussex, United Kingdom: Wiley-Blackwell; 2013:161-167.
101. AABB. Emerging infectious disease agents and their potential threat to transfusion safety. http://www.aabb.org/tm/eid/pages/default.aspx. Accessed 7 January 2019.
102. EUFRAT user manual. Solna, Sweden: European Centre for Disease Prevention and Control; 2018.
103. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012; 367(19):1814-1820.
104. Stramer S, Dodd RY, Chiu CY. Advances in testing technology to ensure transfusion safety: NAT and beyond. ISBT Sci Ser. 2015; 10(suppl 1):55-64.
105. Lombardi VC, Ruscetti FW, Das Gupta J, et al. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome [published correction appears in Science. 2011;334(6053):176] [retracted in Science. 2011;334(6063):1636]. Science. 2009;326(5952):585-589.
106. Lo SC, Pripuzova N, Li B, et al. Detection of MLV-related virus gene sequences in blood of patients with chronic fatigue syndrome and healthy blood donors [published correction appears in Proc Natl Acad Sci USA. 2010;107(44):19132] [retracted in Proc Natl Acad Sci USA. 2012;109(1):346]. Proc Natl Acad Sci USA. 2010;107(36):15874-15879.
107. Simmons G, Glynn SA, Holmberg JA, et al. The Blood Xenotropic Murine Leukemia Virus-Related Virus Scientific Research Working Group: mission, progress, and plans. Transfusion. 2011;51(3):643-653.
108. Lee D, Das Gupta J, Gaughan C, et al. In-depth investigation of archival and prospectively collected samples reveals no evidence for XMRV infection in prostate cancer. PLoS One. 2012;7(9):e44954.
109. Lo SC, Pripuzova N, Li B, et al. [Retracted] Detection of MLV-related virus gene sequences in blood of patients with chronic fatigue syndrome and healthy blood donors [retraction of Proc Natl Acad Sci USA. 2010; 107(36):15874-15879]. Proc Natl Acad Sci USA. 2012;109(1):346.
110. Paprotka T, Delviks-Frankenberry KA, Cingöz O, et al. Recombinant origin of the retrovirus XMRV. Science. 2011;333(6038):97-101.
111. Simmons G, Glynn SA, Komaroff AL, et al; Blood XMRV Scientific Research Working Group (SRWG). Failure to confirm XMRV/ MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study. Science. 2011;334(6057):814-817.
112. Custer B, Janssen MP; Alliance of Blood Operators Risk-Based Decision-Making (RBDM) Initiative. Health economics and outcomes methods in risk-based decision-making for blood safety. Transfusion. 2015; 55(8):2039-2047.
113. Weimer A, Tagny CT, Tapko JB, et al. Blood transfusion safety in sub‐Saharan Africa: a literature review of changes and challenges in the 21st century. Transfusion. 2019;59(1): 412-427.
114. Bloch EM, Vermeulen M, Murphy E. Blood transfusion safety in Africa: a literature review of infectious disease and organizational challenges. Transfus Med Rev. 2012;26(2): 164-180.
115. Opoku-Okrah C, Feglo P, Amidu N, Dakorah MP. Bacterial contamination of donor blood at the Tamale Teaching Hospital, Ghana. Afr Health Sci. 2009;9(1):13-18.
116. Bloch EM, Shah A, Kaidarova Z, et al; Anglophone Africa Transfusion Research Group. A pilot external quality assurance study of transfusion screening for HIV, HCV and HBsAG in 12 African countries. Vox Sang. 2014;107(4):333-342.
117. Laperche S; Francophone African Group for Research in Blood Transfusion. Multinational assessment of blood-borne virus testing and transfusion safety on the African continent. Transfusion. 2013;53(4):816-826.
118. Prugger C, Laperche S, Murphy EL, et al. Screening for transfusion transmissible infections using rapid diagnostic tests in Africa: a potential hazard to blood safety? Vox Sang. 2016;110(2):196-198.
119. Devine DV, Schubert P. Pathogen inactivation technologies: the advent of pathogen-reduced blood components to reduce blood safety risk. Hematol Oncol Clin North Am. 2016;30(3):609-617.
120. Leach Bennett J, Devine DV. Risk-based decision making in transfusion medicine. Vox Sang. 2018;113(8):737-749.
121. Custer B, Hoch JS. Cost-effectiveness analysis: what it really means for transfusion medicine decision making. Transfus Med Rev. 2009;23(1):1-12.
122. Wald M. Blood industry shrinks as transfusions decline. New York, NY: The New York Times; 22 August 2014.
123. Klein HG, Hrouda JC, Epstein JS. Crisis in the sustainability of the U.S. blood system. N Engl J Med. 2017;377(15):1485-1488.
124. Busch MP. Transfusion-transmitted viral infections: building bridges to transfusion medicine to reduce risks and understand epidemiology and pathogenesis. Transfusion. 2006;46(9):1624-1640.
125. Busch MP. Lessons and opportunities from epidemiologic and molecular investigations of infected blood donors. Transfusion. 2006; 46(10):1663-1666.
126. Lanteri MC, Kleinman SH, Glynn SA, et al. Zika virus: a new threat to the safety of the blood supply with worldwide impact and implications. Transfusion. 2016;56(7): 1907-1914.
127. Custer B, Stramer SL, Glynn S, Williams AE, Anderson SA. Transfusion-transmissible infection monitoring system: a tool to monitor changes in blood safety. Transfusion. 2016; 56(6 Pt 2):1499-1502.
128. Dodd RY, Notari EP, Nelson D, et al; NHLBI Retrovirus Epidemiology Donor Study (REDS)-II. Development of a multisystem surveillance database for transfusion-transmitted infections among blood donors in the United States. Transfusion. 2016; 56(11):2781-2789.
129. Kleinman S, King MR, Busch MP, et al. The National Heart, Lung, and Blood Institute retrovirus epidemiology donor studies (Retrovirus Epidemiology Donor Study and Retrovirus Epidemiology Donor Study-II): twenty years of research to advance blood product safety and availability. Transfus Med Rev. 2012;26(4):281-304.
130. Kleinman S, Busch MP, Murphy EL, Shan H, Ness P, Glynn SA; National Heart, Lung, and Blood Institute Recipient Epidemiology and Donor Evaluation Study (REDS-III). The National Heart, Lung, and Blood Institute Recipient Epidemiology and Donor Evaluation Study (REDS-III): a research program striving to improve blood donor and transfusion recipient outcomes. Transfusion. 2014; 54(3 Pt 2):942-955.